April 22nd- Hepta-Refractory Myeloma: When Targets Disappear

CME Congresses .

April 22nd- Hepta-Refractory Myeloma: When Targets Disappear

April 20th- Beyond the webinar: Non-Transfusion-Dependent Thalassemia: From Observation to Intervention

CME Congresses .

April 20th- Beyond the webinar: Non-Transfusion-Dependent Thalassemia: From Observation to Intervention

April 13th- Dr. Florian Simon- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

CME Congresses .

April 13th- Dr. Florian Simon- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

CME Congresses .

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

April 7th- Beyond the Webinar: Menin Inhibitors in AML – From Biology to Clinical Impact

CME Congresses .

April 7th- Beyond the Webinar: Menin Inhibitors in AML – From Biology to Clinical Impact

April 6th- Access to Therapy in Multiple Myeloma: From Innovation to Equity

CME Congresses .

April 6th- Access to Therapy in Multiple Myeloma: From Innovation to Equity

March 30th- Dr. Andres Ramirez Gamero- Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

CME Congresses .

March 30th- Dr. Andres Ramirez Gamero- Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

March 23rd- Zanubrutinib in High-Risk CLL: Changing the Prognosis of del(17p)/TP53 Disease

CME Congresses .

March 23rd- Zanubrutinib in High-Risk CLL: Changing the Prognosis of del(17p)/TP53 Disease

March 19th- Beyond the webinar: CAR-T Cell Therapy: Are We Entering a New Therapeutic Era?

CME Congresses .

March 19th- Beyond the webinar: CAR-T Cell Therapy: Are We Entering a New Therapeutic Era?

March 17th- Beyond the webinar: CARTITUDE-4 long-term follow-up: Is early CAR-T changing the natural history of relapsed myeloma?

CME Congresses .

March 17th- Beyond the webinar: CARTITUDE-4 long-term follow-up: Is early CAR-T changing the natural history of relapsed myeloma?